ClinicalTrials.gg
Not yet recruitingNCT07714473Updated Jul 20, 2026

Evaluation of the Therapeutic Effect of Local Application of Tranexamic Acid in Rotator Cuff Repair

An interventional study of Tranexamic Acid and Normal Saline in Rotator Cuff Tear Repair, sponsored by Hua Luo. Not yet recruiting at 1 site in China. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2026-07-20.

Sponsored by Hua Luo · Not applicable, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
60
Allocation
Randomized
Ages
18 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 28 studies in Rotator Cuff Injuries with a site in China — 14 open to participants now, 14 under way, 1 of them phase 3. Rotator Cuff Injuries · China.

Planned enrollment
9th of 18
60 · median 59
Started
2026
with 3 others
No phase
15 of 28
10 open now
Primary completion
2026-11
later than 7 of 13 live
Registered
27th of 28
by date
Lead sponsor
1 of 28
Hua Luo

Among the 28 studies in Rotator Cuff Injuries with a site in China, this one is the 9th largest by planned enrollment of the 18 interventional ones that give a count, is one of 4 that started in 2026, is one of 15 with no phase, reaches primary completion later than 7 of the 13 other live ones, and was the 27th registered.

Rotator Cuff Injuries

632 studies on the registry are indexed under Rotator Cuff Injuries; 157 are open to participants now.

Browse Rotator Cuff Injuries studies →

Open to participants now

14 of the 28 studies in Rotator Cuff Injuries with a site in China are open now. Recruiting first, the newest first:

8 more — sign in →

All 14 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 100 Rotator Cuff Injuries studies recruiting now, 40 (40%) set no upper age limit and 41 (41%) stop at 75 or younger; 9 take children under 18; 10 take healthy volunteers.

This study: 18 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 28 studies in Rotator Cuff Injuries with a site in China, or all of them as a file.
02

Study summary

This prospective randomized controlled trial aims to evaluate the efficacy and safety of intraosseous tranexamic acid administration during arthroscopic rotator cuff repair. Eligible patients undergoing arthroscopic rotator cuff repair will be randomly assigned in a 1:1 ratio to receive either intraosseous tranexamic acid or intraosseous normal saline placebo. Tranexamic acid will be administered at a dose of 15 mg/kg through intraosseous injection into the proximal humerus after anesthesia induction.

The primary outcome will be intraoperative arthroscopic visual clarity assessed using a five-grade visual clarity scoring system during different surgical stages. Secondary outcomes will include irrigation fluid volume, operative time, and frequency of irrigation pressure adjustments. Safety outcomes will include perioperative complications and laboratory assessments.

This study will determine whether intraosseous tranexamic acid can improve visualization of the arthroscopic surgical field and optimize surgical conditions during rotator cuff repair.

03

Conditions studied

  • Rotator Cuff Tear Repair

Browse trials for

04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age between 18 and 80 years;
  • Patients diagnosed with rotator cuff tear by shoulder MRI;
  • Patients scheduled for arthroscopic rotator cuff repair;
  • Ability to understand the study and provide written .

Exclusion criteria

Exclusion Criteria:

  • Severe open injury or infection around the surgical area;
  • Allergy to tranexamic acid;
  • Previous shoulder surgery;
  • Coagulation disorders;
  • Current anticoagulant therapy that cannot be discontinued;
  • Pregnancy.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Outcomes assessor)
Enrollment
60 participants (estimated)

Study arms

  • Experimental
    Intraosseous Tranexamic Acid Group

    Participants receive intraosseous tranexamic acid administration at a dose of 15 mg/kg into the proximal humeral cancellous bone after anesthesia induction before arthroscopic rotator cuff repair.

    Drug: Tranexamic Acid

  • Placebo comparator
    Placebo Control Group

    Participants receive an equivalent volume of normal saline through intraosseous injection into the proximal humeral cancellous bone after anesthesia induction before arthroscopic rotator cuff repair.

    Drug: Normal Saline

Interventions

  • Tranexamic acid (15 mg/kg) is administered through intraosseous injection into the proximal humeral cancellous bone after anesthesia induction before arthroscopic rotator cuff repair.

  • DrugNormal Saline

    Participants receive an equivalent volume of normal saline through intraosseous injection into the proximal humeral cancellous bone after anesthesia induction before arthroscopic rotator cuff repair.

06

What researchers measure

Primary outcomes

  1. Arthroscopic Visual Clarity Score

    Intraoperative arthroscopic visual clarity will be assessed during different surgical stages, including glenohumeral joint debridement, acromioplasty, and rotator cuff repair. A five-grade visual clarity scoring system will be used: Grade 1: Extremely poor visualization due to severe active bleeding. The surgical field cannot be adequately visualized and the procedure cannot proceed normally. Grade 2: Poor visualization with substantial bleeding interference. Surgical manipulation is significantly affected and additional hemostatic procedures are required. Grade 3: Moderate visualization. Mild to moderate bleeding is present and partially interferes with visualization, but surgery can proceed after routine management. Grade 4: Good visualization. Only minimal bleeding points are present, with limited interference and no requirement for additional hemostatic intervention. Grade 5: Excellent visualization. The surgical field is clear with no visible bleeding points and optimal visua

    Time frame: During arthroscopic rotator cuff repair surgery

Secondary outcomes

  1. Irrigation Fluid Volume

    Total volume of irrigation fluid (mL) used during arthroscopic rotator cuff repair.

    Time frame: During surgery

  2. Operative Time

    Duration of arthroscopic rotator cuff repair procedure. (Min)

    Time frame: During surgery

07

Study locations

1 site
08

References and documents

Publications

  • Zhao J, Liang G, Huang H, Hong K, Pan J, Yang W, Liu J, Zeng L. Intravenous Tranexamic Acid Significantly Improved Visualization and Shortened the Operation Time in Arthroscopic Rotator Cuff Repair: A Systematic Review and Meta-analysis of Level I and II Studies. Arthroscopy. 2024 Feb;40(2):592-601. doi: 10.1016/j.arthro.2023.06.055. Epub 2023 Jul 7. PubMed 37423470 ↗
  • Xue X, Zhuang X, Zhou X, Zhu W, Lou J, Yang X, Li N. Tranexamic Acid Reduces Bleeding and Early Pain but Does Not Improve Intraoperative Visualization in Arthroscopic Rotator Cuff Repair: A Systematic Review and Meta-analysis. Arthroscopy. 2026 Mar;42(3):669-680. doi: 10.1002/arj.70089. Epub 2026 Mar 19. PubMed 41856504 ↗
  • Tran SQ, Itthipanichpong T, Limskul D, Thamrongskulsiri N, Tanpowpong T. Intravenous Tranexamic Acid Is Marginally Inferior to Epinephrine Irrigation for Visual Clarity During Arthroscopic Rotator Cuff Repair: A Double-Blind, Randomized Controlled Trial. Arthroscopy. 2025 Nov;41(11):4460-4468. doi: 10.1016/j.arthro.2025.05.034. Epub 2025 Jun 5. PubMed 40482981 ↗
  • Shin HJ, You HS, Lee K, Je LG, Kim SG, Yang KS, Jeong WK. Intravenous Tranexamic Acid Improves Visual Clarity During Synovectomy in Patients Undergoing Arthroscopic Rotator Cuff Repair: A Double-Blind, Randomized Controlled Study. Arthroscopy. 2024 May;40(5):1409-1419. doi: 10.1016/j.arthro.2023.10.019. Epub 2023 Oct 27. PubMed 37890542 ↗

Individual participant data

Plan to share: No — IPD will not be shared because no public data sharing plan has been established for this study.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Aug 2026; primary completion for Nov 2026, 3 months later.

Of 228 non-industry interventional studies with no phase under Rotator Cuff Injuries, half reached primary completion within 19 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 39. This study's planned 3 months is below that.

Counting every sponsor, half of 252 studies reached it within 23 months; a quarter within 11 and three quarters within 44.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 15, 2026
First posted
Jul 20, 2026
StartEst.
Aug 1, 2026
Primary completionEst.
Nov 30, 2026
CompletionEst.
Dec 30, 2026
Last update
Jul 20, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 20, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07714473
Lead sponsor
Hua Luo
Responsible party
Hua Luo (Doctor, Taizhou Hospital) — Sponsor-investigator
First posted
Jul 20, 2026
Start date
Aug 1, 2026 (estimated)
Primary completion
Nov 30, 2026 (estimated)
Completion
Dec 30, 2026 (estimated)
Last update
Jul 20, 2026

Study contacts

Hua Luo
Contact
luohua66ry@163.com
0576-85190460

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Jul 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Tranexamic Acid

Start the discussion